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Abstract
Influenza virus poses a difficult challenge for protective immunity. This virus is adept at altering its surface proteins, the
proteins that are the targets of neutralizing antibody. Consequently, each year a new vaccine must be developed to combat
the current recirculating strains. A universal influenza vaccine that primes specific memory cells that recognise conserved
parts of the virus could prove to be effective against both annual influenza variants and newly emergent potentially
pandemic strains. Such a vaccine will have to contain a safe and effective adjuvant that can be used in individuals of all ages.
We examine protection from viral challenge in mice vaccinated with the nucleoprotein from the PR8 strain of influenza A, a
protein that is highly conserved across viral subtypes. Vaccination with nucleoprotein delivered with a universally used and
safe adjuvant, composed of insoluble aluminium salts, provides protection against viruses that either express the same or an
altered version of nucleoprotein. This protection correlated with the presence of nucleoprotein specific CD8 T cells in the
lungs of infected animals at early time points after infection. In contrast, immunization with NP delivered with alum and the
detoxified LPS adjuvant, monophosphoryl lipid A, provided some protection to the homologous viral strain but no
protection against infection by influenza expressing a variant nucleoprotein. Together, these data point towards a vaccine
solution for all influenza A subtypes.
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Introduction
Each year influenza virus A causes significant mortality and
morbidity. These global outbreaks occur because of mutations or
exchanges of the genes coding for the viral surface proteins,
hemagglutinin and neuraminidase, processes known as antigenic
drift and shift respectively [1]. Consequently, antibodies induced
by prior viral exposure or vaccination are less likely to recognise
and neutralise new variants. Current influenza vaccines are re-
designed annually based on the sequences of the viruses predicted
to dominate in the following year [2].
The unpredictable nature of antigenic changes makes it difficult
to forecast which viral subtypes are likely to be circulating,
strengthening interest in universal influenza vaccines [1–3].
Appropriately designed vaccines could be used to induce cross
reactive antibodies against conserved portions of the viral surface
proteins [4–6]. Alternatively, a cross reactive vaccine could take
advantage of internal, less variable, proteins. For example,
nucleoprotein (NP) is 90% conserved across viral variants with
HLA class I and II epitopes often conserved [7–10]. Indeed, the
presence of cross reactive T cell immunity is associated with
protection in humans [11–13] and animals studies in which NP is
delivered either as a recombinant protein with various adjuvants,
in DNA vaccines, or in recombinant viruses or bacteria, have
demonstrated that NP specific immunity is protective [14–19].
Many studies of potential influenza vaccines have used
adjuvants or delivery methods that have not been approved for
widespread use in humans. We recently demonstrated that, in
mice, CD8 T cells specific for the Db NP immunodominant
epitope, NP366–74, primed with the universally used adjuvant,
aluminium salts (alum), provide some protection from infectious
challenge with an influenza A virus that expressed the same NP
sequence as the priming antigen [16]. Addition of monopho-
sphoryl lipid A (MPL), a detoxified form of LPS, improved the
protective capacity of the vaccine. This approach is of limited
value in an outbred population in which specific NP epitopes will
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Figure 1. NP protein delivered with alum primes a specific T and B cell immune response. B6 mice were immunized i.m. in both hind-legs
with a total of 10 mg of NP protein delivered with or without 100 mg of alum. The percentages (A, B) or numbers (C, D) of Db/NP366–74 CD8 or IA
b/
NP311–25 CD4 T cells were examined in the spleen or the two popliteal lymph nodes (DLN) 9 days later. Cells are gated on CD8+dump negative live
cells (A) or CD4+dump negative live cells (B) with the number in the plot indicating the percentage of CD8 or CD4 cells that are CD44hi tetramer+ as
indicated by the gate. In C and D each point represents a mouse and the line shows the mean of the group. The X axis is set at the level of detection,
determined by staining cells from naı¨ve animals with the MHC tetramers. Serum from these animals was used to examine the level of NP specific IgG1
antibody (E), with each line representing one animal. These data are combined from 2 independent experiments with 3 mice per group.
doi:10.1371/journal.pone.0061775.g001
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vary depending on the individual’s MHC type. This prompted us
to determine whether similar, or even better, protection could be
obtained following immunization with whole NP.
Here we report that immunization of mice with recombinant
NP and alum provides protection to influenza A challenge with
viruses that either express the same NP as the immunizing antigen
or a variant. We have examined the immune response and level of
protection in C57BL/6 mice as this allows us to assess the adaptive
endogenous T cell response using MHC tetramers in addition to
the evaluating the antibody response using a NP specific ELISA.
Following immunization and subsequent challenge with influenza
viruses that express the same or a distinct NP, protection was
associated with the presence of NP specific CD8 T cells in the
lungs. In contrast to our previous study, the addition of MPL to
the vaccination did not increase protection. Rather, the addition of
MPL inhibited the protection afforded by vaccination with NP
and alum.
This current study offers evidence for a safe, effective universal
influenza vaccine strategy that could greatly reduce the economic,
medical and human costs of influenza infection.
Materials and Methods
Mice and Infections
All animal experiments carried out in this study were done so at
National Jewish Health in strict accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health. The protocol was approved by
the National Jewish Health Institutional Animal Care and Use
Committee (IACUC), protocol number: AS2787. Mice were
maintained in a specific-pathogen-free environment and all efforts
were made to minimize suffering.
Female C57BL/6 (B6) mice (The Jackson Laboratory) were age-
matched within experiments and primed at 7–10 weeks of age with
10 mg of NP protein delivered with 100 mg of alum (Alhydrogel,
Brenntag) with or without 10 mg of MPL (Invivogen). Proteins
were tumbled with alum with/out MPL for 2 hours at room
temperature prior to injection. Mice were immunized intramus-
cularly (i.m.) in both hind-legs. Infections with A/Puerto Rico/8/
34 (PR8) or pandemic H1N1 influenza A virus, A/New York/
1682/2009 (NY1682) [20] were carried out on mice anesthetized
with isofluorane and 50 ml of PBS containing 3PFU of PR8 or
4PFU NY1682-WT virus injected i.n. These doses were used as
previous experiments showed that they led to approximately 20%
weight loss in infected naı¨ve animals. NY1682-WT was supplied
by Dr. David Wentworth (J.Craig Venter Institute, USA). The
virus was prepared following infection of confluent MDCK cells
with virus stock for one hour. After four days of incubation,
supernatant containing the virus was harvested and cell debris
removed. Viral stocks were aliquoted and stored at 280uC.
NP Protein
The NP sequence of PR8 was cloned from a pcDNA construct
from Dr. Paul Digard (Cambridge University, UK) into a
baculovirus expression vector. A His tag was cloned into the C-
terminus. Hi5 cells were infected with the NP-encoding baculo-
virus and cultured for three days at 27uC. The infected cells were
collected, lysed and the supernatant treated with DNase and
Figure 2. NP protein delivered with alum provides optimal protection from influenza A infection. B6 mice were immunized i.m. in both
hind-legs with PBS (closed triangles) or a total of 10 mg of NP protein delivered alone (closed diamonds), or with 10 mg of MPL (closed circles), 100 mg
alum (closed squares), or both adjuvants (open squares). At least 70 days later, these animals were infected with PR8 influenza A i.n. Mice were
weighed daily and the percent of original weight calculated (A) or the amount of virus present in one lung lobe examined 4–5 days after infection (B).
Data are combined from two separate experiments with 4–5 mice per group. In A, significant differences between the PBS control mice infected with
PR8 and the experimental groups are indicated by the following symbol on the indicated days post-infection. Significant differences in mice
immunized with NP and alum are indicated by **(p,0.01) and ***(p,0.001). Significant difference in mice immunized with NP and MPL are indicated
by ## (p,0.01). Significant differences in mice immunized with NP and alum and MPL are indicated by $ (p,0.05), $$ (p,0.01), $$$ (p,0.001). No
significant difference between control PBS mice and those immunized with NP protein were found. In B, * = p,0.05.
doi:10.1371/journal.pone.0061775.g002
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RNase. The protein was purified on a nickel column and
endotoxin removed by treatment with triton X which was then
removed using BioBeads (BioRad). The NP contained #3.5EU or
0.007 ng of LPS per injection, determined by the limulus
amebocyte lysate test (Lonza). The purified protein was run on a
protein gel that was stained with coomassie blue to confirm purity
(Figure S1).
Flow Cytometry
Lymph nodes and spleens were prepared at the indicated times
and red blood cells lysed. One lung lobe taken from perfused mice
was cut into small pieces and treated with collagenase and DNase
(both from Sigma-Aldrich). Single cell suspensions were stained
with MHC tetramers at 37uC for 2 hours. APC-Db/NP366–74 and
PE-Db/PA224–38 were produced as described [21], PE-IA
b/NP311–
25 tetramer was provided by the NIH Tetramer Core Facility.
Antibodies to surface proteins were added and the cells incubated
for a further 20 minutes at 4uC. The antibodies used were: anti-
CD4 or anti-CD8 APC-eFluor780, anti-B220, anti-F4/80, anti-
CD4 eFluor450, anti-CD44 PerCP-Cy5.5 all from eBioscience,
and anti-CD8 pacific blue, anti-CD27 FITC, anti-CD127 PE,
anti-CCR7-APC, and anti-CCR7 biotin and also streptavidin Pe-
Cy7 from BD.
In all cases, 2–5 million events were collected on a CyAn ADP
(Dakocytomation), and data analyzed using FlowJo version 8 or 9
(Treestar). Tetramer+ cells were defined by gating on live (based
on forward-side scatter characteristics), CD8 or CD4 cells that
were negative for the following antigens (the dump gate): B220,
F4/80, MHC class II and either CD4 or CD8 depending on
whether the cells expected to bind the tetramer were MHCI or
MHCII restricted.
ELISA for NP Specific Antibodies
Serum was prepared from venous blood collected by cardiac
puncture and seperated by centrifugation following clotting. The
serum was frozen at 220C before analysis (within one month of
collection). 96-well immulon plates (Thermo) were coated with the
recombinant NP protein at 10 mg/ml in PBS. The plates were
blocked with 10%FCS/PBS before serum samples were added
and titrated. To determine relative units, we titrated, on each
plate, serum from B6 mice containing NP specific IgG1 and
IgG2c. The samples were incubated overnight at 4uC. Plates were
washed and alkaline phosphatase conjugated anti-IgG1 or anti-
IgG2a detection antibodies (Becton Dickinson) added. After the
addition of p-nitrophenyl phosphate substrate, 405 nm absor-
bance was detected using an Elx808 microplate reader.
Plaque Assay for Viral Titres
One lung lobe from mice infected 4–5 days previously was
homogenized and supernatants frozen until use. A final concen-
tration of 2 mg/ml TPCK trypsin was added to the diluted
supernatant which was plated on confluent MDCK cells. The cells
were incubated for 1 hour at 37uC, the supernatants removed,
then 1% SeaKem agar (Lonza) containing media added and plates
returned to 37uC. 72 hours later, agar containing neutral red was
added and plaques counted after a further 24–36 hours of
incubation.
Statistics
To examine protection from influenza A challenge, the
percentages of original weight on each day after infection in each
experimental group was compared to that in control infected mice.
Data are presented as indicated in the figure legends. The
statistical significances were determined using Student’s two-tailed
T test (when two groups are compared) or ANOVA (when more
than two groups are compared) with GraphPad Prism software
version 4.
Results
NP Protein Delivered with Alum Primes NP Specific T
Cells and B Cells
We produced recombinant A/Puerto Rico/8/34 (PR8) NP
protein in insect cells as this is a cost-effective method of producing
recombinant protein that can easily be scaled up. Indeed, several
bavulovirus based vaccines for human or veterinary use are
available [22]. To demonstrate that our recombinant NP protein
could prime an adaptive immune response, we compared
immunization either with NP protein alone or delivered with
alum following an intramuscular injection. The T cell specific
response was measured by flow cytometry nine days post-
immunization using MHC tetramers that bound either CD8 T
cells specific for the Db epitope, NP366–74, or CD4 T cells specific
for the IAb epitope, NP311–25, (Figure 1 A, B). Antigen specific T
cells were detected in the spleen and draining lymph nodes
(popliteal lymph nodes). The numbers of NP specific CD8 T cells
were higher in the spleen than in the draining lymph nodes,
whereas the reverse was true for NP-specific CD4 T cells.
(Figure 1C, D).
While delivery of NP with alum clearly increased the expansion
of antigen specific CD4 and CD8 T cells, immunization with the
protein alone primed a small but detectable response (background
set by staining cells from naı¨ve age-matched mice with the MHC
tetramers). This occurred despite prior treatment to remove
contaminating nucleic acids and endotoxin (see Materials and
Methods). In contrast, NP specific IgG, measured using an NP
specific ELISA, was only present following immunization in the
presence of adjuvant (Figure 1E).
Immunization with Alum and NP Provides Complete
Protection Against Challenge with an Influenza A Virus
that Expresses NP with the Same Sequence as the
Priming NP
To examine protection afforded by immunization with NP
protein, we infected mice that had been immunized at least 70
days earlier with NP protein administered either alone or with
Figure 3. The NP specific memory T cell response is similar regardless of the adjuvant combination used. The numbers of memory NP
specific memory CD8 (A, B) or CD4 (C, D) T cells were determined in the spleens (A, C) and popliteal lymph nodes (B, D) of B6 mice immunized with
NP protein and alum and MPL or alum at least 70 days previously. Cells were gated as in Figure 1. The data are combined from two independent
experiments with 4 mice per group indicated by each point, the line shows the mean of the group. The X axis is set at the level of detection. n.s. not
significant. The expression of memory markers on either NP specific CD8 (E) or CD4 (F) T cells was examined in the spleen (CD8 T cells) or popliteal
lymph nodes (CD4 T cells) at least 70 days after immunization. Cells are gated on naive/CD44 low CD8 or CD4 T cells (filled histogram) or on Db/NP366–
74 tetramer positive CD8 memory T cells or IA
b/NP311–25 tetramer positive CD4 memory T cells from mice immunized with NP protein and alum (black
dashed line) or alum and MPL (red line). Tetramer positive cells were gated on live CD8 or CD4 positive cells that were negative for B220, F4/80, MHC
II and either CD4 or CD8 respectively. The data show representative plots from 1–2 experiments with 4 mice per group.
doi:10.1371/journal.pone.0061775.g003
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Figure 4. The number of Db/NP366–74 CD8 T cells is increased in protected animals. B6 mice were immunized i.m. in both hind-legs with
PBS or a total of 10 mg of NP protein delivered with 100 mg alum with or without 10 mg of MPL. At least 70 days later these animals were infected with
PR8 influenza A i.n. and the numbers of IAb/NP311–25 CD4+ T cells (A and B) or Db/NP366–74 CD8+ (C and D) were examined in the medistinal lymph
node (A and C) or in one lung lobe (B and D) 5 days after infection. Cells were gated as in Figure 1. Each point represents a mouse and the line shows
the mean of the group. The X axis is set at the level of detection. The relative amounts of NP specific IgG1 (E) and IgG2c (F) antibody in the serum of
these animals were examined prior to and 5 days after infection, error bars show SEM. No NP specific antibodies could be detected at these time
points in mice that had been infected but not immunized. Data are combined from two separate experiments with 4–5 mice per group. n.s.: not
significant.
doi:10.1371/journal.pone.0061775.g004
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alum, MPL or both adjuvants (Figure 2A). These adjuvants were
chosen as they are approved for use in human vaccines [23]. While
the MPL used here is a generic form that may not act in exactly
the same way as that present in licensed vaccines [24], the alum
used in these studies is used in human vaccines [25]. In all the
experiments here, the recombinant NP protein used was from the
PR8 virus. Based on our previous findings using NP366–74
conjugated to an irrelevant protein, we expected that mice primed
with whole NP and a combination of alum and MPL would be
protected to the greatest extent [16]. However, while this group
lost less weight than naı¨ve animals, mice immunized with NP
delivered with alum lost little to no weight. Immunization with NP
protein and MPL provided a level of protection similar to that
generated by immunization with the combination of adjuvants.
The absence of weight loss in the NP and alum immunized mice
was reflected in reduced levels of virus in these animals (Figure 2B).
NP Specific CD8 T Cells in the Lung and Draining Lymph
Node Early After Challenge Correlate with Protection
The surprising finding that protection was more effective in
mice primed with NP delivered with alum rather than the
combination of alum and MPL led us to investigate which
differences in the NP specific response induced by these
immunizations might be responsible for the enhanced protection.
The majority of the NP specific memory CD8 T cells were found
in the spleen regardless of whether the mice were immunized with
NP delivered with alum or alum and MPL (Figure 3A). Although
there were slightly more NP specific memory CD8 T cells in the
lymph nodes (popliteal) of mice immunised with NP and alum
compared to those also immunised with MPL (Figure 3B), the total
numbers of NP specific memory CD8 T cells in these animals were
equivalent. The numbers of NP specific memory CD4 T cells in
lymph nodes and spleens were also similar regardless of whether
NP was administered with alum alone or in combination with
MPL (Figure 3C–D).
It was possible that MPL altered the phenotype of the memory
T cells. However, we found that the memory cells were similar in
terms of the survival molecule, CD127, the chemokine receptor
CCR7, and the costimulatory molecules PD-1 and CD27
(Figure 3C, D). This suggests that the generation of memory T
cells after immunization with the various adjuvants could not
explain the difference in protection.
To determine whether differences in the recall response of the
memory T cells generated by immunization with NP delivered
with alum or alum and MPL could explain the different levels of
protection, we also examined the NP specific T cell response five
days following viral challenge. We chose to examine the immune
Figure 5. The NP amino acid sequence from PR8 and NY1682 influenza viruses differ in known epitopes. Sequence alignment for NP
proteins from PR8 [46] and NY1682 [20]. The IAb and Db binding peptides are highlighted in red and green respectively.
doi:10.1371/journal.pone.0061775.g005
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response five days after infection as this is before we observe any
weight loss in the infected animals and, from our previous studies,
we knew that the primary adaptive immune response to NP was
not consistently measurable at day 5 [16]. Therefore, any T cell or
antibody response present at this time must have been primed by
the prior vaccination.
In the lung draining lymph nodes (the mediastinal lymph nodes)
and the lung, NP specific CD4 T cells were detected in infected
animals previously immunized with NP protein delivered with
either alum or alum and MPL. No significant differences in this
response were apparent between these two groups (Figures 4A and
B), indicating that the enhanced protection observed in mice
primed with alum was not a consequence of a NP specific CD4 T
cell response. In contrast, the CD8 NP specific T cell response was
greater in the mediastinal nodes and in lungs of mice primed with
alum compared to those primed with the combined adjuvants
(Figures 4C and D). This suggests that an enhanced NP specific
Figure 6. NY1682 infection does not prime T cells specific for immunodominant epitopes from PR8’s NP. B6 mice were infected
(bottom) or not (top) with NY1682 i.n. and 25 days later the percentages of Db/PA224–38, D
b/NP366–74 CD8 T cells, or IA
b/NP311–25 CD4 in the MLN were
examined (A). The numbers are the percentages of tetramer+CD44hi cells out of gated CD8+ or CD4+ live cells that were also dump negative. The
serum from these animals was tested for the presence of IgG1 and IgG2c antibody that bound to recombinant PR8 NP with each line representing
one mouse (B).
doi:10.1371/journal.pone.0061775.g006
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CD8 T cell response in the lung and mediastinal nodes might be
the cause of the increased protection.
NP specific antibody has been suggested to provide protection
from influenza A infection in mice [26,27]. We found that
immunization with NP delivered either with alum or alum and
MPL lead to the generation of similar levels of NP specific IgG1
and IgG2c (Figure 4E, F). Following infection, the levels of NP
specific IgG2c increased steadily, and to a similar level, in both
groups while only a modest increase in IgG1 was observed. The
similar antibody response in these groups suggests that antibody is
not responsible for the greater protection in mice immunized with
NP and alum compared to those immunized with NP, alum and
MPL.
PR8 NP Protein Provides Cross Reactive Protection to
Influenza A
While NP is highly conserved, variants do exist [9]. NY1682
was generated from a recombinant wild-type (WT) pandemic
H1N1 influenza A virus, A/New York/1682/2009 (NY1682) [20].
The NP from this virus has 43 differences in amino acid sequence
from that encoded by PR8. The differences include two changes
each in the major peptides presented by Db and IAb to B6 CD8
and CD4 T cells respectively (Figure 5). Probably because of these
differences, CD8 and CD4 T cells specific for PR8 NP peptides
bound to Db or IAb could not be detected in the lymph nodes of
NY1682 primary infected mice (Figure 6A). Cells from these
animals did, however, bind to a Db/PA224–38 tetramer; PA224–38 is
identical in PR8 and NY1682 [20,28]. Moreover, cross reactive
NP specific IgG1 and IgG2c antibodies, detected by ELISAs using
recombinant PR8 NP, were clearly present in the serum of
NY1682 infected animals (Figure 6B).
To determine whether immunization with NP from one virus
would protect from the morbidity caused by infection with a virus
containing a different NP sequence, we immunized mice with NP
from PR8. At least 70 days later these animals were infected with
NY1682. Protection from infection with NY1682 was determined
by weight loss (Figure 7A). Mice immunized with PR8’s NP
delivered with alum and MPL lost about the same amount of
weight as naı¨ve animals. In contrast, while mice immunized with
NP and alum did lose some weight, this was significantly less than
that of the control group at the days of peak weight loss.
We tested whether the protection against weight loss afforded by
vaccination with NP+alum correlated with any component of the
NP specific adaptive immune response. Prior to infection, NP
specific IgG1 and IgG2c responses were not significantly different
between the groups of mice immunized with NP+ alum or
NP+alum+MPL. Infection with NY1682 led to an increase in NP
specific IgG2c but not IgG1 (Figure 7B) indicating that, at least,
the IgG2c antibody recognised the NP from both PR8 and
NY1682. However, these responses were the same in mice primed
with NP delivered with alum or alum and MPL. Therefore, as only
the animals primed with NP and alum showed any protective
response, it seems unlikely that the NP specific antibody
contributed to this protection.
Memory T cells can respond to altered versions of their epitopes
[29], therefore, we examined whether we could detect NP specific
cells with the IAb/NP311–25 and D
b/NP366–74 tetramers containing
the PR8 NP peptide sequences. No CD4 T cells that bound to the
IAb/NP311–25 tetramer above background levels could be detected
in either the mediastinal lymph node or the lung (data not shown).
Reactivated Db/NP366–74 tetramer positive CD8 T cells were only
detected in the lungs of mice primed with NP and alum then
challenged with NY1682 (Figure 7C, D). Therefore, as following
challenge with PR8, protection was associated with an early lung
NP specific memory CD8 T cell response.
Discussion
A universal influenza vaccine must protect against the virus
regardless of viral subtype. By definition, the target must be well
conserved and recognizable by an appropriate arm of the immune
response. For this purpose, nucleoprotein fits the bill. There is
evidence that NP might constitute a useful vaccine since, both in
mice and humans, NP specific T cells can kill virally infected cells
[12,13,30,31]. We show that NP fully protects mice against
pathology when the animals are challenged with virus expressing
the immunizing NP sequence. The vaccine affords partial
protection when mice are challenged with influenza expressing a
different NP sequence. The NP of this challenge virus, NY1682,
differs from that of PR8 at 43 out of 498 residues including two
amino acid differences in each of the major peptides recognized by
immunodominant CD4 and CD8 T cells. Despite this, we found
that protection from the weight loss associated with influenza
infection correlated with the presence of reactivated NP specific
memory CD8 T cells in the lungs of the challenged mice.
To prime protective T cells by vaccination, some form of
adjuvant is required. From a practical standpoint, a safe and
widely used adjuvant offers the best approach. Here we have
shown that delivery of NP to mice in the presence of alum primes
at least some protective immunity against influenza. Importantly,
alum delivered vaccines have been shown to prime IFNc
producing CD8 T cells in humans immunized with hepatitis B
vaccine [32,33]. Therefore, it is conceivable that an alum
containing influenza vaccine would also prime CD8 T cells in
humans.
While the live attenuated influenza vaccine is an attractive and
feasible vaccine, the US CDC does not recommend its use in
individuals under 2 or over 49 years of age, populations at
substantial risk of complications following influenza infection [34].
Furthermore, the efficacy of this vaccine declines as early as a year
following immunization perhaps because of the relatively short
lifespan of mucosal immunity [35,36]. A safe sub-unit vaccine
capable of augmenting or, in individuals not exposed to influenza,
priming, cross reactive immunity would be of tremendous value.
Figure 7. Immunization with PR8’s NP and alum primes protective immunity to NY1682. B6 mice were injected i.m. in both hind-legs with
PBS (closed triangles) or a total of 10 mg of NP and 100 mg of alum with (open squares) or without (closed squares) 10 mg of MPL. At least 70 days
later, these animals were infected with NY1682 i.n. The mice were weighed daily and the percent of original weight of each mouse calculated for each
day. The data are combined from two experiments with 4–5 mice per group (A). These mice were bled one day prior to infection with NY1682 or 5
days following infection. The relative units of NP specific IgG1 and IgG2c present in the serum were determined using a NP specific ELISA (B). The
percentages (C) or numbers (D) of Db/NP366–74 tetramer+ cells present in one lung lobe of these and naı¨ve control animals were examined. In A,
significant differences between the PBS control mice infected with NY1682 and those first immunized with PR8’s NP and alum are indicated with
*(p,0.05) and **(p,0.01). No significant differences between PBS control mice and those first immunized with PR8’s NP and alum and MPL were
found. In C, cells were gated on live CD8+ lymphocytes that were dump negative. Representative plots are shown from 1 experiment with 4 mice per
group with numbers in the plot indicating the percentages of Db/NP366–74 tetramer+ out of gated live CD8+ cells. In D, each point represents a mouse
and the line shows the mean of the group. The X-axis is set at the level of background staining.
doi:10.1371/journal.pone.0061775.g007
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The trivalent influenza vaccine does contain some NP protein
and can boost NP specific T cell responses [37–39]. In the US,
however, this vaccine is given in the absence of an added adjuvant
and is, therefore, unlikely to prime a protective cytotoxic CD8 T
cell response. By adding alum and additional NP to the current
vaccine, a multi-layered adaptive anti-influenza immune response
will be induced offering a greater range of protection to the virus.
Outside of the US, influenza vaccines containing either MF59 or
ASO3 are available [40]. These adjuvanted vaccines can improve
the anti-influenza antibody response to hemagglutinin and
neuraminidase, whether they are capable of inducing protective
influenza specific CD8 T cell responses is not known [41,42].
We examined the NP specific adaptive immune response
induced by immunization and following subsequent viral chal-
lenge. We used a mouse influenza infection model as this allowed
us to determine the presence and phenotype of NP specific T cells
following priming and following infection in the appropriate
immune and peripheral organs. These experiments provide crucial
information about which components of the adaptive immune
response are involved in the protective response. However, mouse
infections models do not always provide an accurate reflection of
human immunity and these experiments would need to be
validated in other influenza infection models.
The distinct protective response offered by immunization with
NP delivered with alum in the absence or presence of MPL
provided us with an opportunity to examine correlates of
protection. The NP specific CD4 T cell and antibody responses
were similar in animals immunized and challenged with the
homologous PR8 virus regardless of whether MPL was present in
the immunization. In addition, the antibody response following
infection with NY1682, the influenza that expresses a distinct NP
from PR8, was similar regardless of the adjuvants present in the
immunization. Therefore, it seems unlikely that either the CD4 T
cell or antibody responses could be responsible for the superior
protection found in mice immunized with NP and alum alone.
In contrast, the presence of NP specific CD8 T cells in the lung
draining lymph node and the lung itself correlated with reduced
weight loss following infection with either an homologous virus or
a virus that expressed an altered NP protein compared to that
present in the vaccine. We tested protection following a dose of
influenza that caused a sublethal infection in naı¨ve mice. At higher
doses of the virus the protection we observed may have been
reduced. In our previous study, we also observed that protective
immunity to influenza that expressed an homologous NP
correlated with the presence of NP specific CD8 T cells in the
lung at early timepoints after infection [16]. NP specific CD8 T
cells in the lung that kill infected cells are known to provide
protection from influenza, suggesting that in our studies, these cells
provide protection via this mechanism [19,43,44].
The adjuvants that primed the best protection differed between
our two studies. In our first study we primed only NP specific CD8
T cells. In this case a combination of alum and MPL induced the
best protection. In the study described here, using intact NP and
thus inducing NP-specific CD4 and CD8 T cells and antibody,
alum alone induced the best protection. The reason for the
difference is currently unclear. Following immunization with NP
protein delivered with alum or alum and MPL, similar numbers of
memory T cells and levels of antibody were generated suggesting
that the generation of immune memory was similar regardless of
the presence of MPL in the immunization. We speculate that
differences in either the CD4 T cell or B cell responses in mice
primed with both adjuvants somehow inhibited the ability of
antigen presenting cells to reactivate the memory CD8 T cells
[45].
We cannot rule out a defect in the generation of functional CD8
memory T cells in mice primed with both adjuvants although this
seems unlikely given that CD8 T cells primed in the presence of
both adjuvants in our previous study were not defective [16]. A
change in the priming site may account for the difference as
antigen and adjuvant was delivered i.p. in the previous study
rather than i.m. in the studies presented here.
Regardless of the reasons for the superior protection following
immunization with NP and alum compared to NP and both
adjuvants, our immunization strategy offers a simple, safe and
effective solution to the challenges of the variability of influenza
virus. A universal influenza vaccine has the potential to offer
significant protection to the world’s population and we show this is
achievable using a safe, widely accepted adjuvant.
Supporting Information
Figure S1 The indicated ng of NP protein were run on a
protein gel stained with coomassie blue. Numbers on the
right indicated molecular weight ladder (L) which was run in the
lane on the furthest right.
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